IgG aCL antibodies (U/m) | 5.1 (1.8) | 5.6 (1.9) | 0.21 |
IgM aCL antibodies (U/m) | 6.1 (4.1) | 6.3 (3.7) | 0.84 |
aCL antibodies elevated (n (%)) | 4 (6.2) | 2 (8.0) | 1.00 |
(IgG/IgM/IgG+IgM) | (0/3/1) | (1/1/0) | — |
Protein C levels (%) | 104 (23) | 84 (25) | <0.001 |
Protein C deficiency (n (%)) | 2 (3.1) | 6 (24.0) | 0.007 |
Protein S levels (%) | 84 (25) | 71 (22) | 0.02 |
Protein S deficiency (n (%)) | 16 (24.6) | 11 (44.0) | 0.12 |
Antithrombin III levels (%) | 108 (14) | 93 (19) | <0.001 |
Antithrombin III deficiency (n (%)) | 3 (4.8) | 7 (28.0) | 0.005 |
Plasminogen (mg/dl) | 97 (14) | 90 (14) | 0.045 |
Plasminogen deficiency (n (%)) | 1 (1.5) | 4 (19.0) | 0.03 |
APC ratio | 2.8 (0.4) | 2.8 (0.4) | 0.74 |
APC resistance (n (%)) | 0 | 2 (8.0) | 0.075 |
Prothrombin 20210A mutation* (n (%)) | 5 (7.7) | 1 (4.0) | 0.88 |
Factor VIII levels (%) | 157 (61) | 192 (70) | 0.02 |
Factor VIII levels elevated (n (%)) | 34 (52.3) | 17 (68.0) | 0.27 |
Factor IX levels (%) | 121 (41) | 121 (36) | 0.95 |
Factor XI levels (%) | 104 (38) | 99 (38) | 0.57 |
Factor XII levels (%) | 106 (41) | 111 (24) | 0.61 |
≥1 coagulation factor deficiency (n (%)) | 12 (18.5) | 2 (8.0) | 0.33 |
≥1 significant thrombotic risk factor† (n (%)) | 6 (9.2) | 11 (44.0) | <0.001 |
≥1 any thrombotic risk factor (n (%)) | 42 (64.6) | 19 (76.0) | 0.43 |
≥2 any thrombotic risk factors (n (%)) | 19 (29.2) | 14 (56.0) | 0.03 |